By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – EraGen Biosciences has received US Food and Drug Administration clearance for its molecular test for herpes simplex virus, the firm said today.

The Madison, Wis.-based company said that its MultiCode-RTx HSV 1&2 Kit received 510(k) market clearance, which it said is the first molecular test for herpes simplex virus to be cleared by FDA. The test uses the firm's novel synthetic DNA base pair isoC:isoG, and detects and types HSV 1 and 2 DNA in vaginal lesions.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: transcript patterns in drug-resistant cancer cells, function of high-altitude adaption gene, and more.

Monitoring gene expression changes could help sniff out athletes using performance-enhancing drugs, New Scientist says.

The University of Southern California lodges a cross-complaint in its legal dispute with the University of California, San Diego, over a large Alzheimer's disease project.

Cornell's Christopher Mason and his colleagues correct their New York City microbiome study to emphasize "the difference between matching fragments of DNA from a species and a pathogen."

Sep
17
Sponsored by
Omicia

This online seminar will provide examples of how commercial and hospital-affiliated clinical labs are successfully developing and deploying high-throughput next-generation sequencing-based testing services for genetic diseases. 

Oct
15
Sponsored by
Parabase

This webinar will discuss the benefits of a rapid targeted next-generation sequencing (TNGS) panel, using dried blood spots, for second-tier newborn metabolic and hearing loss screening and its immediate utility for high-risk diagnostic testing in the neonatal intensive care unit.